<?xml version='1.0' encoding='utf-8'?>
<document id="20220045"><sentence text="Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin." /><sentence text="Casopitant, a novel NK-1 receptor antagonist under investigation for the prevention of postoperative and chemotherapy-induced nausea and vomiting, is a weak to moderate inhibitor of CYP3A and a moderate inducer of CYP2C9 in vitro" /><sentence text=" Furthermore, both CYP enzymes are involved in the metabolism of R- and S-warfarin, respectively" /><sentence text=" This clinical study was conducted to explore the potential drug-drug interaction between casopitant and warfarin" /><sentence text=" In total, 97 healthy participants were enrolled and 54 completed the study" /><sentence text=" Participants received individualized daily dosing of warfarin to an international normalized ratio (INR) of 1" /><sentence text="3 to 2" /><sentence text="3 over a 14-day period (period 1)" /><sentence text=" Immediately following period 1, participants entered period 2 and were randomized to receive either regimen A (oral casopitant [150 mg day 1, 50 mg days 2 and 3] and warfarin [days 1-10]) or regimen B (oral casopitant 60 mg and warfarin [days 1-14])" /><sentence text=" INR assessments were performed daily" /><sentence text=" The steady-state C(max) and AUC of R- and S-warfarin were not altered by regimen A, but R-warfarin AUC was increased 1" /><sentence text="31-fold (90% confidence interval [CI]: 1" /><sentence text="22, 1" /><sentence text="41), and S-warfarin AUC was increased 1" /><sentence text="27-fold (90% CI: 1" /><sentence text="18, 1" /><sentence text="38) on day 14 in regimen B" /><sentence text=" Steady-state INR values were not affected by either casopitant regimen" /><sentence text="" /></document>